Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Herz
Erschienen in: Herz 7/2010

01.10.2010 | Schwerpunkt/CME

Stamm- und progenitorzellbasierte Therapieansätze

Aktuelle Entwicklungen zur Behandlung des akuten Myokardinfarkts und der chronischen ischämischen Kardiomyopathie

verfasst von: C. Templin, MD, T.F. Lüscher, U. Landmesser, MD

Erschienen in: Herz | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die perkutane koronare Revaskularisation sowie eine optimierte medikamentöse Therapie können bei Patienten mit akutem Myokardinfarkt das linksventrikuläre (LV) Remodeling und die LV-Dysfunktion reduzieren. Trotz dieser modernen Therapiestrategien entwickelt ein nicht unerheblicher Teil dieser Patienten ein ungünstiges kardiales Remodeling, das mit einer schlechten Prognose einhergeht. Stamm- und progenitorzellbasierte Ansätze für die Behandlung des akuten Myokardinfarkts und der chronischen ischämischen Kardiomyopathie werden als potenzielle neue therapeutische Optionen intensiv untersucht. Diese Übersicht fasst die aktuellen Entwicklungen in der stamm- und progenitorzellbasierten Therapie bei ischämischer Herzerkrankung zusammen. Dabei erfolgt eine Einschätzung der Reparatur- und Regenerationsfähigkeit verschiedener Stamm- und Progenitorzellpopulationen. Darüber hinaus werden die Vor- und Nachteile der verschiedenen kardialen Applikationsformen der Zellen und mögliche neue Strategien zur Funktionsverbesserung von Stamm- und Progenitorzellen für den Einsatz der zellbasierten kardiovaskulären Therapie dargestellt.
Literatur
1.
Landmesser U, Drexler H (2005) Chronic heart failure: an overview of conventional treatment versus novel approaches. Nat Clin Pract Cardiovasc Med 2(12):628–638PubMed
2.
Ford ES, Ajani UA, Croft JB et al (2007) Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 356(23):2388–2398PubMed
3.
Segers VF, Lee RT (2008) Stem-cell therapy for cardiac disease. Nature 451(7181):937–942PubMed
4.
Landmesser U, Wollert KC, Drexler H (2009) Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res 81(3):519–527PubMed
5.
Landmesser U (2009) Bone marrow cell therapy after myocardial infarction. What should we select? Eur Heart J 30(11):1310–1312PubMed
6.
Schachinger V, Erbs S, Elsasser A et al (2006) Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355(12):1210–1221PubMed
7.
Laake LW van, Passier R, Doevendans PA, Mummery CL (2008) Human embryonic stem cell-derived cardiomyocytes and cardiac repair in rodents. Circ Res 102(9):1008–1010PubMed
8.
Nelson TJ, Martinez-Fernandez A, Yamada S et al (2009) Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 120(5):408–416PubMed
9.
Rao MS (2004) Stem sense: a proposal for the classification of stem cells. Stem Cells Dev 13(5):452–455PubMed
10.
Brignier AC, Gewirtz AM (2010) Embryonic and adult stem cell therapy. J Allergy Clin Immunol 125(2 Suppl 2):S336–344PubMed
11.
Morrison SJ, Shah NM, Anderson DJ (1997) Regulatory mechanisms in stem cell biology. Cell 88(3):287–298PubMed
12.
Menasche P (2008) Skeletal myoblasts and cardiac repair. J Mol Cell Cardiol 45(4):545–553PubMed
13.
Menasche P, Hagege AA, Vilquin JT et al (2003) Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 41(7):1078–1083PubMed
14.
Assmus B, Schachinger V, Teupe C et al (2002) Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106(24):3009–3017PubMed
15.
Hirsch A, Nijveldt R, Vleuten PA van der et al (2006) Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial – a prospective, multicenter, randomized trial. Am Heart J 152(3):434–441PubMed
16.
Wollert KC, Meyer GP, Lotz J et al (2004) Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 10–16;364(9429):141–148
17.
Templin C, Kotlarz D, Faulhaber J et al (2008) Ex vivo expanded hematopoietic progenitor cells improve cardiac function after myocardial infarction: role of beta-catenin transduction and cell dose. J Mol Cell Cardiol 45(3):394–403PubMed
18.
Murry CE, Soonpaa MH, Reinecke H et al (2004) Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428(6983):664–668PubMed
19.
Mangi AA, Noiseux N, Kong D et al (2003) Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9(9):1195–1201PubMed
20.
Aicher A, Brenner W, Zuhayra M et al (2003) Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 107(16):2134–2139PubMed
21.
Giannotti G, Doerries C, Mocharla P et al (2010) Impaired in vivo endothelial repair capacity of early endothelial progenitor cells in prehypertension – relation to endothelial dysfunction. Hypertension 55:1389–1397PubMed
22.
Sorrentino SA, Bahlmann FH, Besler C et al (2007) Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 116(2):163–173PubMed
23.
Beltrami AP, Barlucchi L, Torella D et al (2003) Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114(6):763–776PubMed
24.
Laugwitz KL, Moretti A, Lam J et al (2005) Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 433(7026):647–653PubMed
25.
Oh H, Bradfute SB, Gallardo TD et al (2003) Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA 100(21):12313–12318PubMed
26.
Laflamme MA, Chen KY, Naumova AV et al (2007) Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 25(9):1015–1024PubMed
27.
Guan K, Wagner S, Unsold B et al (2007) Generation of functional cardiomyocytes from adult mouse spermatogonial stem cells. Circ Res 100(11):1615–1625PubMed
28.
Abkowitz JL, Catlin SN, McCallie MT, Guttorp P (2002) Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. Blood 100(7):2665–2667PubMed
29.
Pittenger MF, Martin BJ (2004) Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 95(1):9–20PubMed
30.
Kawamoto A, Iwasaki H, Kusano K et al (2006) CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation 114(20):2163–2169PubMed
31.
Losordo DW, Schatz RA, White CJ et al (2007) Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 115(25):3165–3172PubMed
32.
Stamm C, Kleine HD, Choi YH et al (2007) Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg 133(3):717–725PubMed
33.
Urbich C, Dimmeler S (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95(4):343–353PubMed
34.
Hur J, Yoon CH, Kim HS et al (2004) Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 24(2):288–293PubMed
35.
Sieveking DP, Buckle A, Celermajer DS, Ng MK (2008) Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol 51(6):660–668PubMed
36.
Gruh I, Beilner J, Blomer U et al (2006) No evidence of transdifferentiation of human endothelial progenitor cells into cardiomyocytes after coculture with neonatal rat cardiomyocytes. Circulation 113(10):1326–1334PubMed
37.
Landmesser U, Engberding N, Bahlmann FH et al (2004) Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110(14):1933–1939PubMed
38.
(Tomita S, Li RK, Weisel RD et al (1999) Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 100 (Suppl):II247–256
39.
Conget PA, Minguell JJ (1999) Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 181(1):67–73PubMed
40.
Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317PubMed
41.
Makino S, Fukuda K, Miyoshi S et al (1999) Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103(5):697–705PubMed
42.
Schuleri KH, Amado LC, Boyle AJ et al (2008) Early improvement in cardiac tissue perfusion due to mesenchymal stem cells. Am J Physiol Heart Circ Physiol 294(5):H2002–2011PubMed
43.
Toma C, Pittenger MF, Cahill KS et al (2002) Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105(1):93–98PubMed
44.
Planat-Benard V, Menard C, Andre M et al (2004) Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ Res 94(2):223–229PubMed
45.
Planat-Benard V, Silvestre JS, Cousin B et al (2004) Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 109(5):656–663PubMed
46.
Challen GA, Little MH (2006) A side order of stem cells: the SP phenotype. Stem Cells 24(1):3–12PubMed
47.
Kim BO, Tian H, Prasongsukarn K et al (2005) Cell transplantation improves ventricular function after a myocardial infarction: a preclinical study of human unrestricted somatic stem cells in a porcine model. Circulation. 112 (Suppl):I96–104
48.
Iwasaki H, Kawamoto A, Willwerth C et al (2009) Therapeutic potential of unrestricted somatic stem cells isolated from placental cord blood for cardiac repair post myocardial infarction. Arterioscler Thromb Vasc Biol 29(11):1830–1835PubMed
49.
Menasche P, Alfieri O, Janssens S et al (2008) The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117(9):1189–1200PubMed
50.
Dib N, Dinsmore J, Lababidi Z et al (2009) One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). JACC Cardiovasc Interv 2(1):9–16PubMed
51.
Hierlihy AM, Seale P, Lobe CG et al (2002) The post-natal heart contains a myocardial stem cell population. FEBS Lett 530(1–3):239–243
52.
Smith RR, Barile L, Messina E, Marban E (2008) Stem cells in the heart: what’s the buzz all about? – Part 1: preclinical considerations. Heart Rhythm 5(5):749–757PubMed
53.
Messina E, De Angelis L, Frati G et al (2004) Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 95(9):911–921PubMed
54.
Li Z, Lee A, Huang M et al (2009) Imaging survival and function of transplanted cardiac resident stem cells. J Am Coll Cardiol 53(14):1229–1240PubMed
55.
Guan K, Nayernia K, Maier LS et al (2006) Pluripotency of spermatogonial stem cells from adult mouse testis. Nature 440(7088):1199–1203PubMed
56.
Smith AG (2001) Embryo-derived stem cells: of mice and men. Annu Rev Cell Dev Biol 17:435–462PubMed
57.
Crisostomo PR, Abarbanell AM, Wang M et al (2008) Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions. Am J Physiol Heart Circ Physiol 295(4):H1726–1735PubMed
58.
Min JY, Yang Y, Sullivan MF et al (2003) Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. J Thorac Cardiovasc Surg 125(2):361–369PubMed
59.
Nussbaum J, Minami E, Laflamme MA et al (2007) Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 21(7):1345–1357PubMed
60.
Caspi O, Huber I, Kehat I et al (2007) Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. J Am Coll Cardiol 50(19):1884–1893PubMed
61.
Passier R, Laake LW van, Mummery CL (2008) Stem-cell-based therapy and lessons from the heart. Nature 453(7193):322–329PubMed
62.
Murry CE, Keller G (2008) Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132(4):661–680PubMed
63.
Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872PubMed
64.
Yu J, Vodyanik MA, Smuga-Otto K et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858):1917–1920PubMed
65.
Mauritz C, Schwanke K, Reppel M et al (2008) Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 118(5):507–517PubMed
66.
Okita K, Nakagawa M, Hyenjong H et al (2008) Generation of mouse induced pluripotent stem cells without viral vectors. Science 322(5903):949–953PubMed
67.
Kim D, Kim CH, Moon JI et al (2009) Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 4(6):472–476PubMed
68.
Zhang J, Wilson GF, Soerens AG et al (2009) Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 104(4):e30–41PubMed
69.
Barbash IM, Chouraqui P, Baron J et al (2003) Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 108(7):863–868PubMed
70.
Strauer BE, Brehm M, Zeus T et al (2002) Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106(15):1913–1918PubMed
71.
Sherman W, Martens TP, Viles-Gonzalez JF, Siminiak T (2006) Catheter-based delivery of cells to the heart. Nat Clin Pract Cardiovasc Med 3 (Suppl 1):S57–64PubMed
72.
Perin EC, Lopez J (2006) Methods of stem cell delivery in cardiac diseases. Nat Clin Pract Cardiovasc Med 3 (Suppl 1):S110–113PubMed
73.
Thompson CA, Nasseri BA, Makower J et al (2003) Percutaneous transvenous cellular cardiomyoplasty. A novel nonsurgical approach for myocardial cell transplantation. J Am Coll Cardiol 41(11):1964–1971PubMed
74.
Price MJ, Chou CC, Frantzen M et al (2006) Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. Int J Cardiol 111(2):231–239PubMed
75.
Templin C, Kotlarz D, Marquart F et al (2006) Transcoronary delivery of bone marrow cells to the infarcted murine myocardium: feasibility, cellular kinetics, and improvement in cardiac function. Basic Res Cardiol 101(4):301–310PubMed
76.
Tossios P, Krausgrill B, Schmidt M et al (2008) Role of balloon occlusion for mononuclear bone marrow cell deposition after intracoronary injection in pigs with reperfused myocardial infarction. Eur Heart J 29(15):1911–1921PubMed
77.
Vulliet PR, Greeley M, Halloran SM et al (2004) Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs. Lancet 363(9411):783–784PubMed
78.
Freyman T, Polin G, Osman H et al (2006) A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 27(9):1114–1122PubMed
79.
Moscoso I, Barallobre J, Ilarduya OM de et al (2009) Analysis of different routes of administration of heterologous 5-azacytidine-treated mesenchymal stem cells in a porcine model of myocardial infarction. Transplant Proc 41(6):2273–2275PubMed
80.
Makela J, Anttila V, Ylitalo K et al (2009) Acute homing of bone marrow-derived mononuclear cells in intramyocardial vs. intracoronary transplantation. Scand Cardiovasc J 43(6):366–373PubMed
81.
Smits PC, Geuns RJ van, Poldermans D et al (2003) Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol 42(12):2063–2069PubMed
82.
Fukushima S, Varela-Carver A, Coppen SR et al (2007) Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation 115(17):2254–2261PubMed
83.
Melo LG, Pachori AS, Kong D et al (2004) Gene and cell-based therapies for heart disease. FASEB J 18(6):648–663PubMed
84.
Raake P, Degenfeld G von, Hinkel R et al (2004) Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. J Am Coll Cardiol 44(5):1124–1129PubMed
85.
Abdel-Latif A, Bolli R, Tleyjeh IM et al (2007) Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 167(10):989–997PubMed
86.
Hristov M, Heussen N, Schober A, Weber C (2006) Intracoronary infusion of autologous bone marrow cells and left ventricular function after acute myocardial infarction: a meta-analysis. J Cell Mol Med 10(3):727–733PubMed
87.
Lipinski MJ, Biondi-Zoccai GG, Abbate A et al (2007) Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 50(18):1761–1767PubMed
88.
Martin-Rendon E, Brunskill SJ, Hyde CJ et al (2008) Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 29(15):1807–1818PubMed
89.
Bartunek J, Vanderheyden M, Vandekerckhove B et al (2005) Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 112 (Suppl):I178–183PubMed
90.
Reffelmann T, Konemann S, Kloner RA (2009) Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy. J Am Coll Cardiol 53(4):305–308PubMed
91.
Meyer GP, Wollert KC, Lotz J et al (2009) Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 30(24):2978–2984PubMed
92.
Janssens S, Dubois C, Bogaert J et al (2006) Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367(9505):113–121PubMed
93.
Erbs S, Linke A, Schachinger V et al (2007) Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. Circulation 116(4):366–374PubMed
94.
Schachinger V, Erbs S, Elsasser A et al (2006) Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 27(23):2775–2783PubMed
95.
Assmus B, Rolf A, Erbs S et al (2010) Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 3(1):89–96PubMed
96.
Meyer GP, Wollert KC, Lotz J et al (2006) Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months‘ follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113(10):1287–1294PubMed
97.
Lunde K, Solheim S, Forfang K et al (2008) Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months‘ follow-up. J Am Coll Cardiol 51(6):674–676PubMed
98.
Tendera M, Wojakowski W, Ruzyllo W et al (2009) Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre myocardial regeneration by intracoronary infusion of selected population of stem cells in acute myocardial infarction (REGENT) trial. Eur Heart J 30(11):1313–1321PubMed
99.
Seeger FH, Tonn T, Krzossok N et al (2007) Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 28(6):766–772PubMed
100.
Schachinger V, Assmus B, Britten MB et al (2004) Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 44(8):1690–1699PubMed
101.
Sanchez PL, Sanz-Ruiz R, Fernandez-Santos ME, Fernandez-Aviles F (2010) Cultured and freshly isolated adipose tissue-derived cells: fat years for cardiac stem cell therapy. Eur Heart J 31(4):394–397PubMed
102.
Burt RK, Loh Y, Pearce W et al (2008) Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 299(8):925–936PubMed
103.
Orlic D, Kajstura J, Chimenti S et al (2001) Bone marrow cells regenerate infarcted myocardium. Nature 410(6829):701–705PubMed
104.
Gnecchi M, Zhang Z, Ni A, Dzau VJ (2008) Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 103(11):1204–1219PubMed
105.
Kocher AA, Schuster MD, Szabolcs MJ et al (2001) Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7(4):430–436PubMed
106.
Giordano FJ, Gerber HP, Williams SP et al (2001) A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A 98(10):5780–5785PubMed
107.
Uemura R, Xu M, Ahmad N, Ashraf M (2006) Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 98(11):1414–1421PubMed
108.
Urbich C, Aicher A, Heeschen C et al (2005) Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 39(5):733–742PubMed
109.
Burchfield JS, Iwasaki M, Koyanagi M et al (2008) Interleukin-10 from transplanted bone marrow mononuclear cells contributes to cardiac protection after myocardial infarction. Circ Res 103(2):203–211PubMed
110.
Gnecchi M, He H, Liang OD et al (2005) Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11(4):367–368PubMed
111.
Mirotsou M, Zhang Z, Deb A et al (2007) Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci USA 104(5):1643–1648PubMed
112.
Luecke N, Templin C, Muetzelburg MV et al (2010) Secreted proteome of the murine multipotent hematopoietic progenitor cell line DKmix. Rapid Commun Mass Spectrom 24(5):561–570PubMed
113.
Kinnaird T, Stabile E, Burnett MS et al (2004) Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 94(5):678–685PubMed
114.
Yoon CH, Koyanagi M, Iekushi K et al (2010) Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment. Circulation 121(18):2001–2011PubMed
115.
Lunde K, Solheim S, Aakhus S et al (2006) Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 355(12):1199–1209PubMed
116.
Hofmann M, Wollert KC, Meyer GP et al (2005) Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111(17):2198–2202PubMed
117.
Schachinger V, Aicher A, Dobert N et al (2008) Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation 118(14):1425–1432PubMed
118.
Vasa M, Fichtlscherer S, Aicher A et al (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89(1):E1–7PubMed
119.
Imanishi T, Moriwaki C, Hano T, Nishio I (2005) Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens 23(10):1831–1837PubMed
120.
Pons J, Huang Y, Arakawa-Hoyt J et al (2008) VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun 376(2):419–422PubMed
121.
Pons J, Huang Y, Takagawa J et al (2009) Combining angiogenic gene and stem cell therapies for myocardial infarction. J Gene Med 11(9):743–753PubMed
122.
Tang J, Wang J, Yang J et al (2009) Mesenchymal stem cells over-expressing SDF-1 promote angiogenesis and improve heart function in experimental myocardial infarction in rats. Eur J Cardiothorac Surg 36(4):644–650PubMed
123.
Zhao T, Zhang D, Millard RW et al (2009) Stem cell homing and angiomyogenesis in transplanted hearts are enhanced by combined intramyocardial SDF-1alpha delivery and endogenous cytokine signaling. Am J Physiol Heart Circ Physiol 296(4):H976–986PubMed
124.
Templin C, Kotlarz D, Rathinam C et al (2008) Establishment of immortalized multipotent hematopoietic progenitor cell lines by retroviral-mediated gene transfer of beta-catenin. Exp Hematol 36(2):204–215PubMed
125.
Yang J, Zhou W, Zheng W et al (2007) Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology 107(1):17–29PubMed
126.
Cheng Z, Ou L, Zhou X et al (2008) Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 16(3):571–579PubMed
127.
Tang YL, Tang Y, Zhang YC et al (2005) Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 46(7):1339–1350PubMed
128.
Zaruba MM, Theiss HD, Vallaster M et al (2009) Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 4(4):313–323PubMed
129.
Spyridopoulos I, Haendeler J, Urbich C et al (2004) Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 110(19):3136–3142PubMed
130.
Shao H, Tan Y, Eton D et al (2008) Statin and stromal cell-derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells 26(5):1376–1384PubMed
131.
Rooij E van, Marshall WS, Olson EN (2008) Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 103(9):919–928PubMed
132.
Suarez Y, FernandezHernando C, Pober JS, Sessa WC (2007) Dicer-dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 100(8):1164–1173PubMed
133.
Suarez Y, Sessa WC (2009) MicroRNAs as novel regulators of angiogenesis. Circ Res 104(4):442–454PubMed
134.
Maisch B (2010) Regeneration in der Kardiologie – Innovation oder Illusion?. Herz 35:307–308
135.
Bergmann MW, Jaquet K, Schneider C et al (2010) Aktuelle Datenlage zur interventionellen, intramyokardialen Stammzelltherapie bei ischämischer Kardiomyopathie. Herz 35:317–323PubMed
136.
Cebotari S, Tudorache I, Schilling T, Haverich A (2010) Tissue Engineering von Herzklappen und Myokard. Herz 35:334–341PubMed
137.
Kaminski A, Donndorf P, Klopsch C, Steinhoff G (2010) Chirurgische intramyokardiale Stammzelltherapie bei chronischer Myokardischämie. Herz 35:324–333PubMed
Metadaten
Titel
Stamm- und progenitorzellbasierte Therapieansätze
Aktuelle Entwicklungen zur Behandlung des akuten Myokardinfarkts und der chronischen ischämischen Kardiomyopathie
verfasst von
C. Templin, MD
T.F. Lüscher
U. Landmesser, MD
Publikationsdatum
01.10.2010
Verlag
Urban and Vogel
Erschienen in
Herz / Ausgabe 7/2010
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-010-3397-0

Weitere Artikel der Ausgabe 7/2010

Herz 7/2010 Zur Ausgabe

Case study

Reversible congestive heart failure in severe hypocalcemia

Main topic/CME

Intrapericardial procedures for cardiac regeneration by stem cells

Image of the month

Papillary fibroelastoma prolapsing into the left ventricular outflow tract

Cath Lab

Atoll, Access

Original article

Transradial access in percutaneous coronary interventions

Original article

Serial NT-proBNP measurements for risk stratification of patients with decompensated heart failure

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise